Open Access · CC BY-NC-ND 4.0
Treatment of Leukemia Cutis Secondary to T‐Cell Prolymphocytic Leukemia With Upadacitinib
eJHaem · 2026-10 · 7 (5)
DOI: 10.1002/jha2.70396 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 23.09.2026. Verfasst von Kaela Fraser und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dalhousie University Halifax Canada. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
JAK1 inhibitionT‐cell lymphomaleukemia cutisupadacitinib
Autor:innen und Institutionen
- Dalhousie University Halifax Canada.
- Department of Dermatology Dalhousie University Halifax Canada.
- Department of Hematology Dalhousie University Halifax Canada.
ORCID-Profile: Kaela Fraser
Zitieren
APA
Fraser, K., Langille, C., Chen, L. Y. C., & Purdy, K. (2026). Treatment of Leukemia Cutis Secondary to T‐Cell Prolymphocytic Leukemia With Upadacitinib. eJHaem, 7(5). https://doi.org/10.1002/jha2.70396
Vancouver
Fraser K, Langille C, Chen LYC, Purdy K. Treatment of Leukemia Cutis Secondary to T‐Cell Prolymphocytic Leukemia With Upadacitinib. eJHaem. 2026;7(5). doi:10.1002/jha2.70396
BibTeX
@article{Fraser2026,
author = {Fraser, Kaela and Langille, Courtney and Chen, Luke Y C and Purdy, Kerri},
title = {Treatment of Leukemia Cutis Secondary to T‐Cell Prolymphocytic Leukemia With Upadacitinib},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/jha2.70396}
}
EUVIMED